SO-17 A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancerF. Wang, Renjie Xu, Fuxiang Zhou et al.|Annals of Oncology|2022Cited by 5